CRP and COVID-19: REMAP-CAP showed a reduction inmortality as well as in the length of hospital stay and an increase in thenumber of days without organ support.(269) In the RECOVERY trial, a subgroup ofpatients hospitalized with COVID-19 with hypoxemia (SpO2 < 92% orneed for supplemental oxygen) and a C-reactive protein concentration ≥7.5mg/dL was randomized for the administration of tocilizumab (versus placebo),with the majority (> 80%) receiving concomitant corticosteroid therapy andmore than half receiving ventilatory support.